Evidence map›Paper›PMID 42133746›Full record

ArticlePLoS neglected tropical diseases2026

PvGTSeq and PvCRiSP: Two amplicon-based targeted sequencing panels for Plasmodium vivax.

Paulo C Manrique-Valverde, Chloe M Hasund, Katrina A Kelley, Jorge-Eduardo Amaya-Romero, Myriam Arévalo-Herrera, Raphael Brosula, Jose E Calzada, Stella M Chenet, Vladimir Corredor, Angela M Early and 11 more

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Paulo C Manrique-ValverdeDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.ORCID https://orcid.org/0000-0003-3412-0249
Chloe M HasundDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Katrina A KelleyDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Jorge-Eduardo Amaya-RomeroDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Myriam Arévalo-HerreraMalaria Vaccine and Drug Development Center, Cali, Colombia.
Raphael BrosulaInfectious Disease and Microbiome Program, Broad Institute, Cambridge, Massachusetts, United States of America.
Jose E CalzadaUniversidad de Panamá, Panamá, República de Panamá.
Stella M ChenetInstituto de Investigación de Enfermedades Tropicales (IET), Universidad Nacional Toribio Rodríguez de Mendoza de Amazonas (UNTRM), Chachapoyas, Peru.
Vladimir CorredorDepartamento de Salud Pública, Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, Colombia.
Angela M EarlyInfectious Disease and Microbiome Program, Broad Institute, Cambridge, Massachusetts, United States of America.
Gustavo FontechaInstituto de Investigaciones en Microbiología, Facultad de Ciencias, Universidad Nacional Autónoma de Honduras, Tegucigalpa, Honduras.
David A Forero-PeñaBiomedical Research and Therapeutic Vaccines Institute, Ciudad Bolívar, Venezuela.
Sócrates HerreraMalaria Vaccine and Drug Development Center, Cali, Colombia.
Justin T LanaClinton Health Access Initiative, Boston, Massachusetts, United States of America.
Margaret LawsDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Reza Niles-RobinNational Malaria Program, Ministry of Health, Georgetown, Guyana.
Nicanor ObaldiaDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Ana M SantamariaUniversidad de Panamá, Panamá, República de Panamá.
Philipp SchwablDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Sarah AuburnGlobal and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Australia.
Daniel E NeafseyDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.

Funding

Viral Genomics: evolution, spread, and host interactionsU19AI110818 · NIAID · BROAD INSTITUTE, INC. · PI NEAFSEY, DANIEL E · 2014 to 2024
$66.5M
The Graduate Program in Tropical Infectious Diseases (GPiTID)T32AI049928 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI Flaminia Catteruccia, Phyllis J. Kanki · 2001 to 2026
$5.0M
NIAID NIH HHS T32 AI049928NIAID NIH HHS U19 AI110818
6 · The paper itself

Abstract

Plasmodium vivax is the main cause of malaria outside of sub-Saharan Africa, and in many settings it presents significant challenges to malaria elimination efforts. Despite some control successes in the Americas, regional annual case counts of malaria have increased by over 25% between 2014 and 2023, largely driven by P. vivax. Genomic surveillance can play a key role in understanding the extent to which disease persistence represents indigenous transmission as opposed to introduction of new strains through migration, and whether specific variants evade control measures. Efforts to make P. vivax genomic surveillance more cost-effective have led to the development of targeted sequencing-based methods, which strike a varying balance between assay sensitivity and breadth/informativeness. We introduce two new highly sensitive multiplexed amplicon sequencing panels for P. vivax: PvGTSeq and PvCRiSP. PvGTSeq requires selective whole-genome amplification (sWGA) and contains 249 amplicons-36 for antimalarial resistance and 213 for population structure-optimized for Latin America but applicable to all continents. PvCRiSP features four highly polymorphic amplicons that operate without sWGA and is designed to estimate complexity of infection (COI), identify instances of clonal transmission, and characterize recurrent episodes. Both panels use a single multiplex PCR with non-proprietary reagents, achieve ≥75% amplicon recovery at parasitemias as low as five parasites/μL, and PvCRiSP remains effective with low quality DNA. PvGTSeq showed high sequencing accuracy (error rate 3.85e-4% - 2.87e-3%), and both panels efficiently detected alleles from minority clones in simulated polyclonal infections. We validated both panels with samples from Colombia, Guyana, Honduras, Panama, and Venezuela, and performed in-silico assessments using data from 16 countries worldwide, confirming that these two panels have high power to discriminate samples and assign global geographic origin to imported cases. These panels will therefore be useful tools for P. vivax molecular surveillance in diverse geographic settings.

Indexed as

Malaria, VivaxPlasmodium vivaxDNA, ProtozoanDrug ResistanceHumansSensitivity and SpecificitySequence Analysis, DNADNA, Protozoan

Identifiers

PMID42133746
PMCPMC13189417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.